JP2013542265A5 - - Google Patents

Download PDF

Info

Publication number
JP2013542265A5
JP2013542265A5 JP2013538943A JP2013538943A JP2013542265A5 JP 2013542265 A5 JP2013542265 A5 JP 2013542265A5 JP 2013538943 A JP2013538943 A JP 2013538943A JP 2013538943 A JP2013538943 A JP 2013538943A JP 2013542265 A5 JP2013542265 A5 JP 2013542265A5
Authority
JP
Japan
Prior art keywords
dihydro
carboxamide
phenyl
isoindole
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542265A (ja
JP6117104B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/060425 external-priority patent/WO2012067965A1/en
Publication of JP2013542265A publication Critical patent/JP2013542265A/ja
Publication of JP2013542265A5 publication Critical patent/JP2013542265A5/ja
Application granted granted Critical
Publication of JP6117104B2 publication Critical patent/JP6117104B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538943A 2010-11-15 2011-11-11 Namptおよびrock阻害薬 Active JP6117104B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41372210P 2010-11-15 2010-11-15
US61/413,722 2010-11-15
US201161474015P 2011-04-11 2011-04-11
US61/474,015 2011-04-11
US201161525405P 2011-08-19 2011-08-19
US61/525,405 2011-08-19
PCT/US2011/060425 WO2012067965A1 (en) 2010-11-15 2011-11-11 Nampt and rock inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017055914A Division JP2017132792A (ja) 2010-11-15 2017-03-22 Namptおよびrock阻害薬

Publications (3)

Publication Number Publication Date
JP2013542265A JP2013542265A (ja) 2013-11-21
JP2013542265A5 true JP2013542265A5 (enExample) 2017-03-16
JP6117104B2 JP6117104B2 (ja) 2017-04-19

Family

ID=45034200

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013538943A Active JP6117104B2 (ja) 2010-11-15 2011-11-11 Namptおよびrock阻害薬
JP2017055914A Pending JP2017132792A (ja) 2010-11-15 2017-03-22 Namptおよびrock阻害薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017055914A Pending JP2017132792A (ja) 2010-11-15 2017-03-22 Namptおよびrock阻害薬

Country Status (24)

Country Link
US (2) US9302989B2 (enExample)
EP (1) EP2640698A1 (enExample)
JP (2) JP6117104B2 (enExample)
KR (1) KR20140009251A (enExample)
CN (1) CN103313968A (enExample)
AR (1) AR083855A1 (enExample)
AU (2) AU2011329233A1 (enExample)
BR (1) BR112013012078A2 (enExample)
CA (1) CA2816594A1 (enExample)
CL (1) CL2013001340A1 (enExample)
CO (1) CO6761389A2 (enExample)
CR (1) CR20130267A (enExample)
DO (1) DOP2013000106A (enExample)
EC (1) ECSP13012993A (enExample)
GT (1) GT201300124A (enExample)
IL (1) IL225862A0 (enExample)
MX (1) MX2013005454A (enExample)
PE (1) PE20140913A1 (enExample)
PH (1) PH12013500975A1 (enExample)
RU (1) RU2013126657A (enExample)
SG (3) SG10202010119TA (enExample)
TW (1) TW201238950A (enExample)
UY (1) UY33726A (enExample)
WO (1) WO2012067965A1 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
SG10202010119TA (en) * 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
JP5872027B2 (ja) * 2011-05-09 2016-03-01 フォーマ ティーエム, エルエルシー. ニコチンアミドホスホリボシルトランスフェラーゼ(nampt)を阻害するためのピペリジン誘導体および組成物
US8569283B2 (en) * 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EP2776393B1 (en) * 2011-11-11 2017-12-20 Abbvie Inc. Nampt inhibitors
WO2013106414A1 (en) * 2012-01-09 2013-07-18 X-Rx, Inc. Tryptoline derivatives having kinase inhibitory activity and uses thereof
JP5925723B2 (ja) * 2012-04-13 2016-05-25 田辺三菱製薬株式会社 アミド誘導体の医薬用途
EP2882718A4 (en) * 2012-08-10 2015-12-23 Hoffmann La Roche PYRAZOL CARBOXAMIDE COMPOUNDS AND COMPOSITIONS AND METHOD OF USE THEREOF
RS63503B1 (sr) 2012-10-05 2022-09-30 Kadmon Corporation Llc Inhibitori rho kinaze
WO2014074715A1 (en) * 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
ES2684776T3 (es) * 2013-01-18 2018-10-04 Bristol-Myers Squibb Company Ftalazinonas e isoquinolinonas como inhibidores de ROCK
WO2014141035A2 (en) * 2013-03-11 2014-09-18 Aurigene Discovery Technologies Limited Fused heterocyclyl derivatives as nampt inhibitors
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
WO2015142001A2 (ko) * 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
EP3172205A1 (en) 2014-07-23 2017-05-31 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
US9673344B2 (en) * 2014-08-07 2017-06-06 Lumeta, Llc Apparatus and method for photovoltaic module with tapered edge seal
CN107108581B (zh) 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
EP3185860A4 (en) 2014-08-29 2018-08-29 The Board of Regents of the University of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
US20160108406A1 (en) * 2014-10-08 2016-04-21 University Of Iowa Research Foundation Method of regulating cftr expression and processing
CN106928252B (zh) * 2015-12-31 2019-09-27 成都先导药物开发股份有限公司 一种抑制rock的化合物及其制备方法与应用
TWI730032B (zh) 2016-01-13 2021-06-11 美商必治妥美雅史谷比公司 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物
EP3431472B1 (en) * 2016-03-17 2023-05-03 Checkmate Therapeutics Inc. Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
WO2017170830A1 (ja) * 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
PL3478679T3 (pl) 2016-07-01 2021-10-25 Pfizer Inc. Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych
JP7155102B2 (ja) 2016-07-07 2022-10-18 ブリストル-マイヤーズ スクイブ カンパニー Rock阻害剤としてのスピロ縮合環尿素
EA201990890A1 (ru) 2016-10-18 2019-10-31 Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
WO2018094362A1 (en) * 2016-11-21 2018-05-24 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors
EP3610018B1 (en) 2017-04-14 2023-06-07 Arizona Board of Regents on Behalf of the University of Arizona Compositions and methods for treating pulmonary fibrosis
US10975167B2 (en) 2017-04-14 2021-04-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
FI3642202T3 (fi) 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
CN107118157A (zh) * 2017-06-23 2017-09-01 南京大学 一类含吡唑骨架的二苯基脲类衍生物抗肿瘤化合物的设计与合成
WO2019014300A1 (en) 2017-07-12 2019-01-17 Bristol-Myers Squibb Company PHENYLACETAMIDES AS ROCK INHIBITORS
JP7234201B2 (ja) 2017-07-12 2023-03-07 ブリストル-マイヤーズ スクイブ カンパニー 心不全の治療のためのrockの5員アミノヘテロ環および5,6-または6,6員二環式アミノヘテロ環の阻害剤
CN110914257B (zh) 2017-07-12 2023-05-26 百时美施贵宝公司 作为rock抑制剂的螺庚基乙内酰脲
TW201908293A (zh) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
US11319295B2 (en) * 2017-10-09 2022-05-03 Merck Sharp & Dohme Corp. Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
EP3746079A1 (en) * 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
RU2732297C2 (ru) * 2018-11-14 2020-09-15 Общество с ограниченной ответственностью "Гурус БиоФарм" Производные нестероидных противовоспалительных средств
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
CN114728926A (zh) * 2019-11-15 2022-07-08 武汉朗来科技发展有限公司 一种rock抑制剂及其制备方法和用途
KR20230038697A (ko) * 2020-07-14 2023-03-21 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 Rock 억제제 및 이의 제조 방법과 용도
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
EP4263524A1 (en) 2020-12-21 2023-10-25 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2023245470A1 (zh) * 2022-06-22 2023-12-28 南方医科大学珠江医院 Mdp类似物在制备用于治疗炎症性肠病的药物中的用途
IL319081A (en) * 2022-09-23 2025-04-01 Sironax Ltd NAMPT modulators, their preparations and uses
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
CN122249422A (zh) * 2023-09-26 2026-06-19 安菲纳治疗公司 杂芳基化合物及其在治疗医学病状中的用途
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025168575A1 (en) 2024-02-05 2025-08-14 Institut National de la Santé et de la Recherche Médicale Inhibitors of nad biosynthesis for the treatment of dengue virus infections
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
US20260183268A1 (en) * 2024-12-27 2026-07-02 Alphina Therapeutics, Inc. Heteroaryl Compounds and Their Use in Treating Medical Conditions
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors
WO2026165047A1 (en) * 2025-01-29 2026-08-06 Rapport Therapeutics, Inc. Nicotinic acetylcholine receptor modulators and uses therein

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH433312A (de) * 1963-10-18 1967-04-15 Dresden Arzneimittel Verfahren zur Herstellung therapeutisch wertvoller Amide der Isoindolin-2-carbonsäure
CH443312A (fr) * 1963-10-29 1967-09-15 Ajinomoto Kk Procédé de préparation du 1-N-oxyde d'hypoxanthine et du 1-N-oxyde d'inosine substituée ou non, et utilisation des produits obtenus par ce procédé poutilisation des produits obtenus par ce procédé pour la préparation de la 2,6-dichloro-purine et 9-B-D-ribofuranosyl purine substitua ée ou non
GB1029326A (en) 1964-03-18 1966-05-11 Dresden Arzneimittel Isoindoline-2-carboxylic acid amides
BE648616A (fr) 1964-05-29 1964-09-16 Dresden Arzneimittel Amides d'acides isoindolin-2-carboxyliques et leur procédé de préparation.
US4419360A (en) 1979-10-31 1983-12-06 Rohm And Haas Company Arthropod repellants
SI9011830B (sl) 1990-09-27 1999-12-31 Univerza V Ljubljani, Fakulteta Za Farmacijo Novi N-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, ki jih vsebujejo
US5726197A (en) * 1992-11-02 1998-03-10 Syntex (U.S.A.) Inc. Isoindolinyl derivatives
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
AU4534696A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
FR2733750B1 (fr) 1995-05-03 1997-06-13 Synthelabo Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique
US6277985B1 (en) 1995-09-15 2001-08-21 Pharmacia & Upjohn Company Aminoaryl oxazolidinone N-oxides
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
KR20010101675A (ko) 1999-01-26 2001-11-14 우에노 도시오 2h-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
AU2002235277A1 (en) * 2000-10-23 2002-05-06 Smith Kline Beecham Corporation Compounds and methods
WO2002081443A1 (en) 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
JP2003277340A (ja) 2002-03-22 2003-10-02 Toray Ind Inc 接着分子阻害剤及び新規アミノ酸誘導体
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
AR042064A1 (es) 2002-11-19 2005-06-08 Takeda Pharmaceutical Compuestos de amina con actividad inhibidora de la union al receptor de somastotina
AU2004207731B2 (en) 2003-01-31 2009-08-13 Sanwa Kagaku Kenkyusho Co., Ltd. Compound inhibiting dipeptidyl peptidase iv
GB0310865D0 (en) 2003-05-12 2003-06-18 Black James Foundation Gastrin and cholecystokinin receptor ligands
WO2004101533A1 (en) 2003-05-12 2004-11-25 Janssen Pharmaceutica, N.V. 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands
EP1660454A1 (en) 2003-07-07 2006-05-31 Vernalis (R&D) Limited Azacyclic compounds as inhibitors of sensory neurone specific channels
EP1659881B1 (en) * 2003-08-06 2019-04-03 Senomyx Inc. Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
CA2534428A1 (en) 2003-08-13 2005-03-03 Paul A. Tempest Melanin concentrating hormone receptor antagonists
WO2005037214A2 (en) * 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2005051945A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treatment and/or prevention of disorders modulated by a ppar
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
EP1749007A2 (en) 2004-03-30 2007-02-07 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
US20060045953A1 (en) 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
ATE412636T1 (de) 2004-12-16 2008-11-15 Hoffmann La Roche Piperazinylpyridinderivate als mittel gegen adipositas
MX2007008008A (es) * 2004-12-30 2007-11-12 Astex Therapeutics Ltd Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
MX2007013049A (es) * 2005-04-19 2008-01-11 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad.
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
WO2007011290A1 (en) 2005-07-18 2007-01-25 Respiratorius Ab Bronchorelaxing agents based on indol- and isoquinoline derivatives
CN101253152A (zh) * 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
BRPI0618523A2 (pt) 2005-11-11 2011-09-06 Hoffmann La Roche compostos de aminas cìclicas fundidas carbocìclicas, composições farmacêuticas e usos dos mesmos
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
JP4047365B2 (ja) * 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
JP4012239B2 (ja) * 2006-01-11 2007-11-21 生化学工業株式会社 オキサゾロン誘導体
BRPI0707916A2 (pt) * 2006-01-13 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
KR101062513B1 (ko) * 2006-02-17 2011-09-06 에프. 호프만-라 로슈 아게 5ht2/d3 조절제로서의 벤조일-피페리딘 유도체
WO2007121124A2 (en) 2006-04-11 2007-10-25 Novartis Ag Hcv inhibitors comprising beta amino acids and their uses
US8148417B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
KR101077295B1 (ko) 2006-05-18 2011-10-26 에프. 호프만-라 로슈 아게 아데노신 a2b 수용체 길항물질로서의 티아졸로-피라미딘/피리딘 우레아 유도체
EP2032554A1 (en) * 2006-05-30 2009-03-11 F. Hoffmann-Roche AG Piperidinyl pyrimidine derivatives
CN101547890A (zh) 2006-08-29 2009-09-30 知识产权和技术办公室 通过用螺硼酸酯进行硼烷还原肟醚而催化不对称合成伯胺
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
CL2007003874A1 (es) * 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
GB0705882D0 (en) 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
WO2008130319A2 (en) 2007-04-23 2008-10-30 Astrazeneca Ab Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
KR20100082349A (ko) * 2007-10-17 2010-07-16 사노피-아벤티스 치환된 n-페닐-비피롤리딘 우레아 및 이의 치료적 용도
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
GB0721332D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
EP2067771A1 (en) 2007-12-03 2009-06-10 EPFL Ecole Polytechnique Fédérale de Lausanne Derivatives of Dihydroxypyrrolidine as Anti-Cancer Compounds
KR20100097725A (ko) 2007-12-05 2010-09-03 아스트라제네카 아베 신규 화합물 ⅲ
WO2009086835A1 (en) 2008-01-11 2009-07-16 Topotarget A/S Novel cyanoguanidines
JP2011088826A (ja) * 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
WO2009118712A2 (en) 2008-03-27 2009-10-01 Ecole Polytechnique Federale De Lausanne (Epfl) Novel dihydroxypyrrolidine derivatives as anti-cancer agents
MX2010014310A (es) 2008-06-24 2011-02-15 Topotarget As Derivados de acido escuarico como inhibidores de la nicotinamida.
CN102186822A (zh) 2008-08-29 2011-09-14 顶标公司 新脲和硫脲衍生物
US20110318266A1 (en) 2008-09-16 2011-12-29 Mccauley John A Phthalimide derivative metabotropic glutamate r4 ligands
CA2739491A1 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
WO2010057101A2 (en) * 2008-11-17 2010-05-20 Schering Corporation Compounds useful as hiv blockers
WO2010066709A1 (en) 2008-12-09 2010-06-17 Topotarget A/S Novel pyridinyl acrylamide derivatives
TW201030007A (en) 2009-02-06 2010-08-16 Gruenenthal Gmbh Substituted spiro-amides as b1r modulators
CA2759264A1 (en) 2009-04-21 2010-10-28 Astellas Pharma Inc. Diacylethylenediamine compound
WO2011006803A1 (en) 2009-07-14 2011-01-20 Nerviano Medical Sciences S.R.L. 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition
BR112012021806A2 (pt) 2010-03-01 2015-09-08 Myrexis Inc compostos e seus usos terapêusticos.
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
CN106986856A (zh) 2010-09-03 2017-07-28 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt抑制剂的4‑{[(吡啶‑3‑基‑甲基)氨基羰基]氨基}苯‑砜衍生物
AR082885A1 (es) 2010-09-03 2013-01-16 Genentech Inc Compuestos y composiciones para la inhibicion de nampt
SG10202010119TA (en) * 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors

Similar Documents

Publication Publication Date Title
RU2013126657A (ru) Ингибиторы nampt и rock
JP2017524007A5 (enExample)
RU2484091C2 (ru) Производные изоксазоло-пиридина
JP5206747B2 (ja) 含窒素複素環化合物およびその医薬用途
JP2011518836A5 (enExample)
RU2016124178A (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
JP2008534496A5 (enExample)
JP2018530591A5 (enExample)
JP2009286777A (ja) 置換アルキルアミン誘導体およびそれの使用方法
RU2014150049A (ru) Ингибиторы nampt
BR112013022761A2 (pt) compostos moduladores heterocíclicos de síntese de lipídios, suas composições e usos
JP2010500994A5 (enExample)
KR100856156B1 (ko) 케모카인 수용체의 조절자로서의3-아미노사이클로펜탄카복스아마이드
AU4971400A (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
BG108013A (bg) Заместени аминопроизводни и методи за използването им
CA2771568A1 (en) Heteroaryl compounds as kinase inhibitors
JP2007518823A (ja) キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
JP2016523911A5 (enExample)
JP2015520752A5 (enExample)
HRP20151064T1 (hr) Amido spojevi i njihova upotreba kao farmaceutski proizvodi
CA2819373A1 (en) Bicyclic compounds as pim inhibitors
EP1358161A2 (en) N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
JP2017516826A (ja) 炎症性および自己免疫性の病気の処置のためのmth1阻害剤
AU2004226165A1 (en) Pyrimidin-4-one derivatives and their use as p38 kinase modulators
JP2010505905A (ja) キナーゼ阻害剤としての置換ピロロ−ピラゾール誘導体